ATE60087T1 - Menschlicher faktor viii, diesen enthaltende zusammensetzungen sowie verfahren und materialien, die fuer seine herstellung verwendung finden. - Google Patents

Menschlicher faktor viii, diesen enthaltende zusammensetzungen sowie verfahren und materialien, die fuer seine herstellung verwendung finden.

Info

Publication number
ATE60087T1
ATE60087T1 AT85302734T AT85302734T ATE60087T1 AT E60087 T1 ATE60087 T1 AT E60087T1 AT 85302734 T AT85302734 T AT 85302734T AT 85302734 T AT85302734 T AT 85302734T AT E60087 T1 ATE60087 T1 AT E60087T1
Authority
AT
Austria
Prior art keywords
manufacture
processes
materials used
compositions containing
factor viii
Prior art date
Application number
AT85302734T
Other languages
English (en)
Inventor
Daniel Jeffrey Capon
Gordon Allen Vehar
Richard Mark Lawn
William Irwin Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24410850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE60087(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE60087T1 publication Critical patent/ATE60087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT85302734T 1984-04-20 1985-04-18 Menschlicher faktor viii, diesen enthaltende zusammensetzungen sowie verfahren und materialien, die fuer seine herstellung verwendung finden. ATE60087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60231284A 1984-04-20 1984-04-20
EP85302734A EP0160457B1 (de) 1984-04-20 1985-04-18 Menschlicher Faktor VIII, diesen enthaltende Zusammensetzungen sowie Verfahren und Materialien, die für seine Herstellung Verwendung finden

Publications (1)

Publication Number Publication Date
ATE60087T1 true ATE60087T1 (de) 1991-02-15

Family

ID=24410850

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85302734T ATE60087T1 (de) 1984-04-20 1985-04-18 Menschlicher faktor viii, diesen enthaltende zusammensetzungen sowie verfahren und materialien, die fuer seine herstellung verwendung finden.

Country Status (23)

Country Link
EP (2) EP0160457B1 (de)
JP (2) JP2799338B2 (de)
KR (1) KR850007275A (de)
AR (1) AR241314A1 (de)
AT (1) ATE60087T1 (de)
AU (2) AU601358B2 (de)
CA (2) CA1341468C (de)
DE (1) DE3581312D1 (de)
DK (1) DK164876C (de)
ES (1) ES8607397A1 (de)
FI (1) FI86885C (de)
GR (1) GR850947B (de)
HK (1) HK8395A (de)
HU (1) HU202275B (de)
IE (1) IE57677B1 (de)
IL (1) IL74909A (de)
LU (1) LU88546I2 (de)
MY (1) MY102029A (de)
NL (1) NL940016I2 (de)
NO (1) NO174934C (de)
NZ (1) NZ211824A (de)
PT (1) PT80292B (de)
ZA (1) ZA852864B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
DE3588242T2 (de) * 1984-01-12 2004-03-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Für Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
US4716117A (en) * 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (de) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
DE3683980D1 (de) * 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
FR2599754B1 (fr) * 1986-06-06 1989-12-29 Transgene Sa Procede de preparation de facteur viii a partir de cellules de mammiferes
EP0254076B1 (de) 1986-07-11 1991-05-08 Miles Inc. Herstellung von rekombinantem Protein
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
DE3730599A1 (de) * 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
JP2872255B2 (ja) * 1987-01-30 1999-03-17 バイオジエン，インコーポレイティド ファクター▲ｖｉｉｉ▼の高収量生産法
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (de) * 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
FR2642767B1 (fr) * 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
JP4723185B2 (ja) * 2001-11-28 2011-07-13 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産方法
CA2491992A1 (en) 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP2359865B1 (de) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Verfahren zur Erhöhung der Funktion eines AAV-Vektors
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
RU2486236C2 (ru) 2006-01-04 2013-06-27 Бакстер Интернэшнл Инк. Способ экспрессии белка
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
AU2011238708B2 (en) 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2675902B1 (de) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Zusammensetzungen und method zur veränderung der gewebespezifität und verbesserung des aav9-vermittleten gentransfers
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3283126B1 (de) 2015-04-16 2019-11-06 Emory University Rekombinante promotoren und vektoren zur proteinexpression in leber und verwendung davon
CN111504887B (zh) * 2020-05-09 2023-05-09 苏州四正柏生物科技有限公司 一种溶血素及其制备方法
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0107278B1 (de) * 1982-08-04 1989-11-15 National Research Development Corporation Molekulare Klonierung des Gens für menschlichen antihaemophilischen Faktor IX
AU572128B2 (en) * 1983-03-31 1988-05-05 Scripps Clinic And Research Foundation New factor viii, coagulant polypeptides and monoclonal antibodies
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
DE3588242T2 (de) * 1984-01-12 2004-03-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Für Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS60224492A (ja) * 1984-04-24 1985-11-08 Yuu Honshiyo 異種遺伝子の結合法

Also Published As

Publication number Publication date
ZA852864B (en) 1986-12-30
EP0385558A2 (de) 1990-09-05
JPH0640942A (ja) 1994-02-15
EP0160457B1 (de) 1991-01-16
NZ211824A (en) 1991-05-28
LU88546I2 (fr) 1995-03-01
EP0160457A1 (de) 1985-11-06
GR850947B (de) 1985-07-17
EP0385558A3 (de) 1990-12-27
FI86885B (fi) 1992-07-15
AU5295890A (en) 1990-08-30
AU601358B2 (en) 1990-09-13
PT80292B (pt) 1987-10-20
HUT37654A (en) 1986-01-23
DK164876C (da) 1993-01-18
JP2799338B2 (ja) 1998-09-17
IL74909A (en) 1992-01-15
IL74909A0 (en) 1985-07-31
JP2777043B2 (ja) 1998-07-16
NL940016I2 (nl) 2000-08-01
HK8395A (en) 1995-01-27
NL940016I1 (nl) 1994-10-17
PT80292A (en) 1985-05-01
CA1341395C (en) 2002-10-22
FI851497L (fi) 1985-10-21
CA1341468C (en) 2004-12-14
DE3581312D1 (de) 1991-02-21
MY102029A (en) 1992-02-29
FI851497A0 (fi) 1985-04-15
JPS60243023A (ja) 1985-12-03
IE57677B1 (en) 1993-02-24
NO174934B (no) 1994-04-25
DK176885D0 (da) 1985-04-19
HU202275B (en) 1991-02-28
KR850007275A (ko) 1985-12-02
NO174934C (no) 1994-08-03
DK164876B (da) 1992-08-31
FI86885C (fi) 1992-10-26
DK176885A (da) 1985-10-21
AR241314A1 (es) 1992-05-29
AU4134585A (en) 1985-10-24
ES8607397A1 (es) 1986-06-01
NO851563L (no) 1985-10-21
ES542296A0 (es) 1986-06-01
IE850998L (en) 1985-10-20

Similar Documents

Publication Publication Date Title
ATE60087T1 (de) Menschlicher faktor viii, diesen enthaltende zusammensetzungen sowie verfahren und materialien, die fuer seine herstellung verwendung finden.
DE93619T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
DE3583757D1 (de) Keramisches material und verfahren zu seiner herstellung.
DE68909712T2 (de) Biomedizinisches Material und Verfahren zu seiner Herstellung.
DE3789348D1 (de) Bioverträgliches zusammengesetztes Material und Verfahren zu seiner Herstellung.
DE3582341D1 (de) N-aryl-3-aryl-4,5-dihydro-1h-pyrazol-1-carboxamide, verfahren zu ihrer herstellung, sie enthaltende insektizide zusammensetzungen und verfahren zur bekaempfung von insekten.
DE69101685T2 (de) Katalytische Eisen-Antimon-Molybdän-Zusammensetzung und Verfahren zur Herstellung derselben.
DE3873718T3 (de) Herstellung von Gegenständen aus gebundenem und aus Einzelteilen bestehendem Material sowie Binderzusammensetzungen für die Verwendung darin.
DE3768338D1 (de) Zusammensetzung, verfahren zur deren herstellung und schichtstoff.
DE3768752D1 (de) Verfahren zur herstellung von werkstoffen aus betatyptitanlegierung von ausgezeichneter festigkeit und dehnung.
DE69006874T2 (de) Verfahren zur Herstellung von Schichtmetallen.
DE3775294D1 (de) Implantatwerkstoff und verfahren zu seiner herstellung.
DE3581097D1 (de) Glaskeramisches material, kondensator aus diesem material und verfahren zur herstellung von letzterem.
DE3785329D1 (de) Harzzusammensetzung und verfahren zur herstellung.
DE69001484T2 (de) Verwendung von menschlichen BCDF für die Herstellung einer Zusammensetzung für die Behandlung von Thrombocytopenia.
DE3584306D1 (de) Verfahren zur herstellung von schutzlackbildern und zusammensetzung dafuer.
ATA257883A (de) Geschirr, insbesondere kochgeschirr, und verfahren zur herstellung desselben
DE3578438D1 (de) Verbessertes siliziumoxynitrid-material und verfahren zu dessen herstellung.
DE3881074T2 (de) Nichtfluechtige, durch ultraviolette strahlung loeschbare halbleiterspeicheranordnung und verfahren zu ihrer herstellung.
DE3854262D1 (de) Harzzusammensetzung und Verfahren zu ihrer Herstellung.
DE3381408D1 (de) Zwischenverbindungen fuer die herstellung von ceftazidin und verfahren zu ihrer herstellung.
DE3577372D1 (de) Verfahren zur herstellung von sonnenzellen aus amorphem silizium und das dadurch erzeugte produkt.
DE3761984D1 (de) Verfahren zur herstellung modifizierter peche und deren verwendung.
ATE8798T1 (de) Kijanimicin, es enthaltende pharmazeutische zusammensetzungen und verfahren zur herstellung von kijanimicin und der zusammensetzungen.
DE3851541D1 (de) Propylen-äthylen-kopolymer-zusammensetzung und verfahren zur herstellung.